# Lipids and Myeloid Cell Function in Cancer

> **NIH NIH R01** · WISTAR INSTITUTE · 2021 · $402,239

## Abstract

Project Summary
Myeloid cells are critical component of tumor microenvironment. Under physiological conditions these cells
are comprised of mature terminally differentiated cells: polymorphonuclear neutrophils (PMN) and other
granulocytes; macrophages (MΦ); and dendritic cells (DCs). In cancer, myeloid compartment is dramatically
affected, which is now considered as one of the major immunological hallmarks of cancer. Tumor-bearing
(TB) hosts accumulate immunosuppressive MΦ, DCs in cancer are ineffective in induction of potent immune
responses. The prominent change in the myeloid compartment in cancer is the expansion of pathologically
activated immature myeloid cells with the potent ability to suppress immune responses – myeloid-derived
suppressor cells (MDSC). In TB mice, the total population of MDSC consists of three groups of cells: the
most abundant (>75%) immature, pathologically activated neutrophils (PMN-MDSC); less abundant (<20%)
population of pathologically activated monocytes - (M-MDSC); and small (<5%) population of early myeloid
precursors. The current view considers changes in myeloid cells separately. Different mechanisms applied to
the different cells. The gap in our knowledge is how these different myeloid cells can interact with each other
in tumor-bearing hosts. In this proposal we will test the hypothesis that oxidized lipids may provide bridge
between different populations of myeloid cells in cancer and orchestrate their abnormal function.
The ultimate goal of this project is not only to better understand the mechanism regulating myeloid cell
function in cancer but to develop novel approaches to regulation of immune responses in cancer.
To achieve this goal we propose the following specific aims:
Specific aim 1. To determine the role of lectin-type oxidized LDL receptor 1 in regulation of PMN-MDSC in
cancer patients
Specific aim 2. To identify the role of oxidized lipids in the function of PMN-MDSC and DCs.

## Key facts

- **NIH application ID:** 10202494
- **Project number:** 5R01CA165065-09
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Valerian E Kagan
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $402,239
- **Award type:** 5
- **Project period:** 2012-09-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10202494

## Citation

> US National Institutes of Health, RePORTER application 10202494, Lipids and Myeloid Cell Function in Cancer (5R01CA165065-09). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10202494. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*